The Effect of Dexamethasone 12 mg vs 6 mg on Thromboembolic Events in Patients With Critical COVID-19

All patients were recruited from the CS2-trial with following inclusion/exclusion criteria: Inclusion Criteria: * confirmed SARS-CoV-2 AND * requiring at least 10l/min of O2 supplementation, non-invasive mechanical ventilation for hypoxia or invasive mechanical AND Exclusion Criteria: * if previously randomised to the CS2 trial * if they had received corticosteroids for COVID-19 during ≥5 consecutive days or use corticosteroids in doses \>6 mg dexamethasone for an indication other than COVID-19. * active tuberculosis * hypersensitivity to dexa-/betamethasone * active fungal infection * fertile woman ≤60 years of age with a positive U-HCG/P-HCG test * informed consent not obtainable For the inclusion in this post-hoc analyses there is additional criteria: Inclusion Criteria: \- randomised in the ICU Exclusion Criteria: * established thromboembolism at randomisation * established major bleeding at randomisation